Bridgebio Pharma, INC 8-K filings

BridgeBio Pharma's stockholders approved the amendment and restatement of the 2021 Stock Option and Incentive Plan, increasing the number of shares reserved for issuance, and elected five directors at their annual meeting on June 21, 2024.

BridgeBio reports sustained positive results from a Phase 2 trial of infigratinib in children with achondroplasia, showing significant improvements in height velocity and body proportionality, and has initiated a study for hypochondroplasia.

BridgeBio Pharma announced strong first quarter 2024 financial results, highlighted by a significant increase in revenue and a substantial capital raise, alongside key clinical and regulatory advancements.

BridgeBio Pharma has launched a public offering of 8,620,690 shares of common stock at $29.00 per share, aiming to raise approximately $250 million.

BridgeBio Pharma has granted Bayer exclusive rights to develop and commercialize acoramidis in Europe, potentially earning up to $310 million in milestone payments.

BridgeBio Pharma announced positive clinical trial updates, including the acceptance of a New Drug Application for acoramidis, and secured up to $1.25 billion in capital.

BridgeBio Pharma has entered into agreements for $1.25 billion in financing, including a royalty agreement tied to acoramidis sales and a new senior secured credit facility.